Your browser doesn't support javascript.
loading
Defining the next generation of Plasmodium vivax diagnostic tests for control and elimination: Target product profiles.
Ding, Xavier C; Ade, Maria Paz; Baird, J Kevin; Cheng, Qin; Cunningham, Jane; Dhorda, Mehul; Drakeley, Chris; Felger, Ingrid; Gamboa, Dionicia; Harbers, Matthias; Herrera, Socrates; Lucchi, Naomi; Mayor, Alfredo; Mueller, Ivo; Sattabongkot, Jetsumon; Ratsimbason, Arsène; Richards, Jack; Tanner, Marcel; González, Iveth J.
Afiliación
  • Ding XC; FIND, Geneva, Switzerland.
  • Ade MP; Department of Communicable Diseases and Health Analysis, Pan American Health Organization/World Health Organization, Washington, DC, Unites States of America.
  • Baird JK; Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia.
  • Cheng Q; The Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Cunningham J; Australian Army Malaria Institute, Brisbane, Australia.
  • Dhorda M; Global Malaria Programme, World Health Organization, Geneva, Switzerland.
  • Drakeley C; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Felger I; World Wide Antimalarial Resistance Network, Churchill Hospital, Oxford, United Kingdom.
  • Gamboa D; Department of Immunology and Infection, London School of Hygiene & Tropical Medicine, London, United Kingdom.
  • Harbers M; University of Basel, Basel, Switzerland.
  • Herrera S; Swiss Tropical and Public Health Institute, Basel, Switzerland.
  • Lucchi N; Institute of Tropical Medicine Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.
  • Mayor A; Departamento de Ciencias Celulares y Moleculares, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru.
  • Mueller I; RIKEN Center for Life Science Technologies, Division of Genomic Technologies, Yokohama, Japan.
  • Sattabongkot J; Caucaseco Scientific Research Center, Cali, Colombia.
  • Ratsimbason A; Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
  • Richards J; ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
  • Tanner M; Centro de Investigação em Saúde da Manhiça (CISM), Maputo, Mozambique.
  • González IJ; Population Health and Immunity Division, Walter and Eliza Hall Institute, Parkville, Australia.
PLoS Negl Trop Dis ; 11(4): e0005516, 2017 04.
Article en En | MEDLINE | ID: mdl-28369085
The global prevalence of malaria has decreased over the past fifteen years, but similar gains have not been realized against Plasmodium vivax because this species is less responsive to conventional malaria control interventions aimed principally at P. falciparum. Approximately half of all malaria cases outside of Africa are caused by P. vivax. This species places dormant forms in human liver that cause repeated clinical attacks without involving another mosquito bite. The diagnosis of acute patent P. vivax malaria relies primarily on light microscopy. Specific rapid diagnostic tests exist but typically perform relatively poorly compared to those for P. falciparum. Better diagnostic tests are needed for P. vivax. To guide their development, FIND, in collaboration with P. vivax experts, identified the specific diagnostic needs associated with this species and defined a series of three distinct target product profiles, each aimed at a particular diagnostic application: (i) point-of-care of acutely ill patients for clinical care purposes; (ii) point-of-care asymptomatic and otherwise sub-patent residents for public health purposes, e.g., mass screen and treat campaigns; and (iii) ultra-sensitive not point-of-care diagnosis for epidemiological research/surveillance purposes. This report presents and discusses the rationale for these P. vivax-specific diagnostic target product profiles. These contribute to the rational development of fit-for-purpose diagnostic tests suitable for the clinical management, control and elimination of P. vivax malaria.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Plasmodium falciparum / Plasmodium vivax / Malaria Vivax / Malaria Falciparum / Sistemas de Atención de Punto Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: PLoS Negl Trop Dis Asunto de la revista: MEDICINA TROPICAL Año: 2017 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Plasmodium falciparum / Plasmodium vivax / Malaria Vivax / Malaria Falciparum / Sistemas de Atención de Punto Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: PLoS Negl Trop Dis Asunto de la revista: MEDICINA TROPICAL Año: 2017 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Estados Unidos